Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. reported its Q3 2025 financial results, highlighting positive new analyses of varoglutamstat data showing a consistent treatment effect in patients with lower baseline eGFR, supporting advancement into stage 3b/4 diabetic kidney disease studies. The company successfully raised EUR 5.1 million through a private placement, extending its cash runway well into Q3 2026, which provides financial flexibility for strategic partnerships. Research and development expenses decreased to EUR 3.7 million for the nine months ended September 30, 2025, compared to EUR 12.6 million in the prior year, contributing to a reduced net loss of EUR 7.6 million. The company also announced a change in CFO, with Marcus Irsfeld succeeding Anne Doering.

Disclaimer*

UK 100

Latest directors dealings